Boston Scientific works toward stents that release less drugs

06/9/2009 | Wall Street Journal, The

To maintain its position in the drug-coated stent market, which is worth more than $4 billion, Boston Scientific acquired Labcoat, which developed technology that allows stents to deliver anti-clotting drugs only for a few months. "We want to explore the lower limit of drug to get us as close to a bare-metal stent as we can, but maintain the efficacy" of the device, said Keith Dawkins, Boston Scientific's associate chief medical officer.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care